Shukra Pharmaceuticals Limited
SHUKRAPHARBSE
₹68.60▼ -0.31 (-0.45%)
Whole company worth₹3,005 Cr
Price for ₹1 of profit₹137
1-year range₹40 – ₹75
The short version
A fast-growing, highly profitable business — priced at a steep premium to what it earns.
What Shukra Pharmaceuticals does
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing
Worked out from Shukra Pharmaceuticals's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Shukra Pharmaceuticals is a small-sized company in pharmaceuticals.
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing
- Whole company is worth
- ₹3,005 crore
- Run by
- Dakshesh Rameshchandra Shah
- Employees
- 115
- Shareholders
- 28,384 people
- Listed since
- 2026
A small company by stock-market value — these tend to move more sharply.
02Is it growing?
Sales have grown 39% a year for 5 years.
At that pace a business doubles in size roughly every 2 years.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹39 as profit.
Here is where the money from Shukra Pharmaceuticals's sales went in FY26, the latest full year it has reported.
₹28
₹13
₹12
₹39
- ₹28Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹13Running the businessstaff, rent, marketing, power and everything else
- ₹1.9Interest on its loansthe cost of borrowed money
- ₹6.1Wear and tearmachines, stores and buildings losing value over time
- ₹12Taxincome tax paid to the government
- ₹39Profit it keepswhat is left for the company's owners
On the money its owners have put in
It earns ₹25 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹25
₹0₹10₹20₹30₹40
That figure is called return on equity (ROE). Above ₹20 is rare and usually means the business has something competitors struggle to copy. For comparison, a bank fixed deposit pays roughly ₹6–7.
Does the profit turn into cash?
For every ₹100 of profit it reported, ₹15 actually came in as cash.
Profit it reported₹50 Cr
Cash its business brought in₹7.3 Cr
Over the last 3 years: ₹50 crore of profit but only ₹7.3 crore of cash. A wide gap like this is worth understanding before trusting the profit figure.
04Is the price high or low?
You pay ₹137 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 137 means buyers are paying for about 137 years of today's profit up front.
The share price over the past year
It is 9% below its highest price of the past year and 71% above its lowest.
05Who owns it?
Its founders and parent group own 51 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 28,384 people and institutions hold its shares.
As filed for the quarter ending 30 Jun 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
Three things going well, one thing worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Sales have compounded at 39% a year.
- Earns ₹25 a year on every ₹100 of shareholders' money.
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- The share price is 137 times a year's profit, so it leans heavily on growth continuing.
07What happened lately?
Latest quarter: sales up 336%.
Apr–Jun 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹24 Cr
▲ 336.4% on a year earlier
Profit
₹13 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Shukra Pharmaceuticals?
This page describes Shukra Pharmaceuticals using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Shukra Pharmaceuticals Limited (SHUKRAPHAR): company summary
The company's business has improved significantly, with annual revenue rising 74.1% and net profit jumping 130.3% year-over-year.
Shukra Pharmaceuticals Limited (SHUKRAPHAR) is a micro-cap Healthcare company valued at ₹3,005 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Shukra Pharmaceuticals Limited last traded at ₹68.6, modestly down 0.45% on the day.
- Recent developments
- On 2026-09-21, the company announced a dividend of ₹0.01 per share, effective from that date. The latest quarter results, ending 2026-06-30, showed a sharp increase in both revenue and net profit compared to the year-ago period, indicating a turnaround in performance.
- Financial performance
- The company's business has improved significantly, with annual revenue rising 74.1% and net profit jumping 130.3% year-over-year. The latest quarter saw revenue surge 336.4% and net profit explode 1,158.3% compared to the same quarter a year earlier, driven by strong growth in recent months.
- Valuation multiples
- The stock trades at 137.2 times earnings, a premium to the Healthcare median of 32.0, 30.12 times book value. It yields 0.0%.
- Things to watch
- The company's revenue growth has slowed in recent years, with a 3-year CAGR of -1.3% and a 5-year CAGR of 38.8%. The stock is currently 8.6% below its 52-week high, and the latest quarter showed a net profit loss of ₹2 crore in March 2026, which contrasts with the strong results in June 2026.
- Where it stands
- Shukra Pharmaceuticals Limited has delivered strong growth in the latest quarter, with revenue and net profit rising sharply compared to the same period a year earlier. The company's net profit margin has improved by 9.5 percentage points, and return on equity remains at 24.6%. The stock is currently 8.6% below its 52-week high.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals
Explore Shukra Pharmaceuticals Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Shukra Pharmaceuticals Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedLaurus Labs LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Shukra Pharmaceuticals Limited with peers
Shukra Pharmaceuticals Limited vs Sun Pharmaceutical Industries LimitedShukra Pharmaceuticals Limited vs Divi's Laboratories LimitedShukra Pharmaceuticals Limited vs Torrent Pharmaceuticals LimitedShukra Pharmaceuticals Limited vs Laurus Labs LimitedShukra Pharmaceuticals Limited vs Zydus Lifesciences LimitedShukra Pharmaceuticals Limited vs Apollo Hospitals Enterprise Limited
Related tools & concepts
Value Shukra Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing